Pfizer Inc (PFE) |
|
52.54 1 (1.94%)
|
01-26 00:30 |
|
Open: |
51.36 |
Pre. Close: |
51.54 |
|
High:
|
52.835 |
Low:
|
51.24 |
|
Volume:
|
40,499,373 |
Market Cap:
|
294,900M |
|
|
|
|
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; Arvinas, Inc.; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
52.906 - 53.202 |
53.202 - 53.473 |
|
Low:
|
50.46 - 50.846 |
50.846 - 51.201 |
|
Close:
|
51.974 - 52.54 |
52.54 - 53.059 |
|
Technical analysis |
as of: 2022-01-25 4:26:21 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 66.77 One year: 72.08 |
| Support: |
Support1: 49.81 Support2: 41.45 |
| Resistance: |
Resistance1: 57.17 Resistance2: 61.71 |
| Pivot: |
54.62  |
| Moving Average: |
MA(5): 52.89 MA(20): 55.45
MA(100): 49.45  MA(250): 43.40 |
| MACD: |
MACD(12,26): -0.70 Signal(9): -0.08 |
| Stochastic oscillator: |
%K(14,3): 20.01 %D(3): 13.29 |
| RSI: |
RSI(14): 41.06 |
| 52-week: |
High: 61.71 Low: 33.36 Change(%): 46.4 |
| Average Vol(K): |
3-Month: 45354 10-Days: 35346 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.PFE has closed above bottom band by 15.0%. Bollinger Bands are 2.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 25 Jan 2022
Pfizer and BioNTech launch trial of Omicron-targeted COVID vaccine - Reuters
Tue, 25 Jan 2022
Is Pfizer a buy on the strength of its new COVID-19 pill? - Seeking Alpha
Tue, 25 Jan 2022
Pfizer Inc. (PFE) is down -4.95% in a Week, Should You Buy? - InvestorsObserver
Mon, 24 Jan 2022
PFE Stock Price: Pfizer Inc keeps falling despite soaring covid cases - FXStreet
Mon, 24 Jan 2022
Should You Invest in Pfizer in 2022? - Motley Fool
Sun, 23 Jan 2022
Pfizer Stock (PFE): Why The Price Fell Today - Pulse 2.0
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. (M) |
5,610 |
| Shares Float (M) |
5,610 |
|
% Held by Insiders
|
0.04 |
|
% Held by Institutions
|
67.45 |
|
Shares Short (K)
|
58,640 |
|
Shares Short P. Month (K)
|
63,560 |
Stock Financials |
|
EPS
|
3.500 |
|
EPS Est This Year
|
2.560 |
|
EPS Est Next Year
|
2.760 |
|
Book Value (p.s.)
|
13.490 |
|
Profit Margin
|
28.68 |
|
Operating Margin
|
32.14 |
|
Return on Assets (ttm)
|
7.8 |
|
Return on Equity (ttm)
|
27.8 |
|
Qtrly Rev. Growth
|
134.4 |
|
Gross Profit (p.s.)
|
5.941 |
|
Sales Per Share
|
12.360 |
|
EBITDA (p.s.)
|
4.868 |
|
Qtrly Earnings Growth
|
454.50 |
|
Operating Cash Flow (M)
|
32,290 |
|
Levered Free Cash Flow (M)
|
42,430 |
Stock Valuations |
|
PE Ratio
|
15.01 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.89 |
|
Price to Sales
|
4.25 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
1.550 |
|
Forward Dividend
|
1.600 |
|
Dividend Yield
|
0.03 |
|
Dividend Pay Date
|
2022-03-03 |
|
Ex-Dividend Date
|
2022-01-26 |
|
7 Binary Options
|
|
Your Ad Here
|
|
